ANI PHARMACEUTICALS INC (ANIP) insider trading

By person

26 insiders · 268 transactions

29.5×

Nikhil Lalwani holds 29.5 times base salary in stock. $24.71M of shares against $837.41K in salary for 2025.

Salary from the company's own proxy. The shares are what Nikhil Lalwani last reported holding, valued at $72.87, the price Common Stock was last bought or sold at on the open market here, on 29 Oct 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Muthusamy Shanmugam

Head of R&D, COO-Novitium Ops

$276.50K (2)

$58.70M (60) scheduled

−$58.43M

532,976

2.37%

$38.84M

—

Meridian Venture Partners II LP entity

10% owner

—

$28.62M (10)

−$28.62M

1,819,259

8.09%

$132.57M

−22.6%

Nikhil Lalwani

President & CEO

$200.00K (1)

$20.35M (12)

−$20.15M

333,689

1.48%

$24.32M

—

Chad Gassert

SVP - Corp. Dev. & Strategy

$275.09K (2)

$15.14M (13) scheduled

−$14.87M

233,406

1.04%

$17.01M

—

Tracy Marshbanks

Director

—

$12.49M (11)

−$12.49M

361,044

1.61%

$26.31M

−35.5%

Stephen P. Carey

SVP & CFO

—

$8.83M (14) scheduled

−$8.83M

166,143

0.7387%

$12.11M

—

Arthur Przybyl

President and CEO

—

$7.80M (11)

−$7.80M

190,309

0.8461%

$13.87M

−12.1%

James G. Marken

SVP Ops & Prod Dev

—

$3.77M (7)

−$3.77M

117,829

0.5239%

$8.59M

+142.2%

Christopher Mutz

Head of Rare Disease

—

$2.86M (11) scheduled

−$2.86M

91,309

0.4060%

$6.65M

—

Robert W Schrepfer

SVP - New Bus Dev & Spec Sales

—

$2.70M (8) scheduled

−$2.70M

87,477

0.3889%

$6.37M

+403.8%

Ori Gutwerg

SVP, Generics

—

$2.68M (10)

−$2.68M

75,534

0.3358%

$5.50M

—

Patrick D Walsh

Director

$707.94K (6)

$3.12M (5)

−$2.42M

38,432

0.1709%

$2.80M

—

Daniel Raynor

Director

—

$2.18M (6)

−$2.18M

300,113

1.33%

$21.87M

−10.2%

Jeanne Thoma

Director

$49.82K (1)

$1.99M (3)

−$1.94M

26,762

0.1190%

$1.95M

+1,684%

Antonio R Pera

Director

$126.79K (1)

$1.82M (4)

−$1.69M

27,017

0.1201%

$1.97M

—

Krista Davis

SVP, Chief HR Officer

—

$1.62M (12) scheduled

−$1.62M

51,946

0.2310%

$3.79M

—

Thomas Haughey

Director

$497.20K (4)

$1.82M (2)

−$1.33M

38,878

0.1729%

$2.83M

—

Meredith Cook

Sr. VP, General Counsel & Sec.

—

$948.18K (36) scheduled

−$948.18K

73,424

0.3265%

$5.35M

—

Matthew J Leonard

Director

—

$840.72K (2)

−$840.72K

11,221

0.0499%

$817.67K

—

Thomas Andrew Rowland

SVP, Head - Established Brands

—

$820.24K (3)

−$820.24K

38,271

0.1702%

$2.79M

+9.6%

Renee P Tannenbaum

Director

—

$273.81K (2)

−$273.81K

29,514

0.1312%

$2.15M

—

David Nash

Director

$99.36K (1)

—

+$99.36K

38,561

0.1714%

$2.81M

—

Robert E. Brown JR

Director

—

49,021

0.2180%

$3.57M

+384.9%

Fred Holubow

Director

—

14,811

0.0659%

$1.08M

+25.4%

Thomas A. Penn

Director

—

14,301

0.0636%

$1.04M

+41.5%

Henry O Gosebruch

Director

—

6,662

0.0296%

$485.46K

—

ANI PHARMACEUTICALS INC

What the insiders did Net selling

By person